DBV Technologies reported $86.22M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amarin USD 473.69M 12.49M Mar/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
DBV Technologies USD 86.22M 83.35M Jun/2025
Halozyme Therapeutics USD 332.75M 149.52M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Insmed USD 1.25B 1.15B Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
PTC Therapeutics USD -206546000 20.79M Jun/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
United Therapeutics USD 7.17B 366.4M Jun/2025